In this episode of the UEG Podcast, our host Pradeep Mundre, together with IBD expert Klaartje Bel Kok, explore the latest breakthroughs in IBD presented at UEG Week 2025 in Berlin.

From long-term IL-23 inhibitor data to novel drugs such as Obefazimod and Tulisokibart, the discussion covers key findings that are reshaping IBD management. Bel dives into new insights on JAK inhibitors in pregnancy, the growing role of ultrasound monitoring in IBD, and the challenge of choice overload in treatment decisions. Tune in for expert reflections on emerging research, collaboration within the IBD community, and the evolving understanding of IBD’s complex aetiology.

• 03:15 PREGNANCY AND INFANT OUTCOMES FOLLOWING IN UTERO EXPOSURE TO JAK INHIBITORS IN WOMEN WITH INFLAMMATORY BOWEL DISEASE: A GLOBAL MULTICENTER COHORT STUDY
• 05:42 CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
• 05:53 A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
• 08:10 Monitoring IBD by imaging
• 09:15 RANDOMIZED CONTROLLED TRIAL COMPARING ENDOSCOPIC BALLOON DILATION VERSUS ENDOSCOPIC STRICTUROTOMY FOR SHORT STRICTURES (< 3 CM) RELATED TO CROHN’S DISEASE (THE BEST-CD TRIAL) (NCT05521867)
• 14:55 DOCTIS: A SINGLE CELL RNA-SEQ ATLAS OF DRUG RESPONSE TO TARGETED THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES
• 16:00 EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES
• 16:18 TL1a